» Authors » Jens H J Bos

Jens H J Bos

Explore the profile of Jens H J Bos including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 47
Citations 336
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Li X, Steenhuis D, Bijlsma M, de Vos S, Mubarik S, Bos J, et al.
Int J Gen Med . 2024 Oct; 17:4947-4958. PMID: 39478851
Purpose: Anti-hyperlipidemic drug treatments are effective in reducing the risk of cardiovascular disease. In a long-term retrospective inception cohort study, we aimed to assess the real-world comparative effectiveness of anti-hyperlipidemic...
2.
Cahyaningsih I, Asiri A, de Vos S, Bos J, Schuiling-Veninga C, Taxis K, et al.
J Clin Med . 2024 Oct; 13(19). PMID: 39407915
: To improve hypoglycaemia management in primary care, more insight is needed into the opportunities to screen for hypoglycaemia risk and subsequent treatment modification using routinely available data. Our primary...
3.
Rollema C, Van Roon E, Schuiling-Veninga N, Bos J, De Vries T
J Allergy Clin Immunol Glob . 2024 Aug; 3(4):100303. PMID: 39211328
Background: To improve (patient-tailored) instructions for intranasal corticosteroid (INC) administration, we need to gain insight into specific characteristics of INC users and comedication use. Objective: We examined INC prescriptions obtained...
4.
Li X, Bijlsma M, de Vos S, Bos J, Mubarik S, Schuiling-Veninga C, et al.
Front Pharmacol . 2024 Jun; 15:1357567. PMID: 38903996
Introduction: Antihypertensive drugs are used preventatively to lower the risk of cardiovascular disease events. Comparative effectiveness studies on angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), beta-blockers (BBs), calcium...
5.
Alghamdi A, Bijlsma M, de Vos S, Schuiling-Veninga C, Bos J, Hak E
Pharmaceuticals (Basel) . 2023 Dec; 16(12). PMID: 38139820
Background: Alzheimer's disease (AD) is the most common cause of dementia, with a growing number of patients worldwide. The association between AD and treatment with drugs targeting the beta-adrenergic receptor...
6.
Li X, Bijlsma M, Bos J, Schuiling-Veninga C, Hak E
BMJ Open . 2023 Aug; 13(8):e068721. PMID: 37558444
Objective: To determine the long-term effectiveness of antihypertensive monotherapies in primary prevention of cardiovascular events. Design: Retrospective inception cohort study covering a 25-year study period. Setting: University Groningen IADB.nl pharmacy...
7.
Robiyanto R, Roos M, Bos J, Hak E, van Puijenbroek E, Schuiling-Veninga C
Arch Womens Ment Health . 2023 Aug; 26(5):685-696. PMID: 37542677
The purpose of the study is to examine the switching pattern and dose adjustment of antidepressants (ADs) prescribed to women from six months before to six months during pregnancy in...
8.
Mommers I, van Boven J, Schuiling-Veninga C, Bos J, Koetsier M, Hak E, et al.
Clin Epidemiol . 2023 Jun; 15:721-732. PMID: 37337562
Purpose: The Global Initiative for Asthma (GINA) suggests a step-wise approach for pharmacological treatment of asthma. Valid study of real-world treatment patterns using dispensing databases includes proper measurement of medication...
9.
Steenhuis D, de Vos S, Bos J, Hak E
Prev Med Rep . 2023 Jun; 34:102258. PMID: 37292425
We aim to identify risk factors of major adverse cardio-cerebrovascular events (MACCE) using a proxy of drug treatment for a MACCE after the start of statin therapy in the primary...
10.
Atmaj E, Schuiling-Veninga C, Tuinen E, Bos J, De Vries T
Pediatr Blood Cancer . 2023 Feb; 70(4):e30231. PMID: 36726028
Background: It has been suggested that childhood asthma lowers the risk of childhood leukaemia. Studies have found an inverse association between these conditions. However, most studies on this relationship are...